Tag Archive for: antibody-drug conjugate

Phase 1 Trial for ITC-6146RO, Antibody-Drug Conjugate Targeting B7-H3

ITC-6146RO is an experimental cancer drug belonging to the class of antibody–drug conjugates, or ADCs. It received IND Approval from Korean Ministry of Food and Drug Safety (Following U.S. FDA) to start a first‑in‑human Phase 1 trial in people with advanced or metastatic solid tumors who no longer respond to standard therapies. It has been […]

IND Required for ITC-6146RO for Solid Tumors Overexpressing the B7-H3 Protein

On August 29, 2025, a clinical trial plan (Investigational New Drug application) was submitted to the Ministry of Food and Drug Safety (MFDS) of South Korea to initiate phase 1 clinical trials for ITC-6146RO. ITC-6146RO is an antibody-drug conjugate (ADC) designed to target solid tumors overexpressing the B7-H3 protein, such as metastatic castration-resistant prostate cancer […]

Phase 1/2 Trial for DS-3939a: A Novel TA-MUC1–Directed ADC for Advanced Prostate Cancer and Beyond